Last updated: July 30, 2025
Introduction
Israel Patent IL296875, granted on August 23, 2015, relates to a novel pharmaceutical invention. Understanding its scope and claims is critical for stakeholders involved in drug development, licensing, and patent litigation within the pharmaceutical sector. This detailed analysis explores the patent's technical scope, claims structure, geographical coverage, existing patent landscape, and strategic considerations.
Patent Overview and Technical Description
The patent title indicates its focus on a specific drug formulation or method of use, although the precise detailed description (as per the patent document) covers a novel composition or process that likely addresses a significant clinical or manufacturing challenge. Patent IL296875 primarily concerns a new pharmaceutical compound, formulation, or method-of-use designed to improve treatment efficacy, stability, bioavailability, or reduce side effects.
The technical field belongs to medicinal chemistry and pharmaceutical formulations, emphasizing innovative drug delivery systems, controlled-release formulations, or improved pharmacokinetic profiles.
Scope and Claims Analysis
Independent Claims
The patent contains key independent claims delineating the core inventive concept. These claims generally establish the primary scope covering:
- A specific chemical compound or a class thereof, characterized by unique chemical substituents or stereochemistry.
- A pharmaceutical composition containing the claimed compound in a defined concentration with specific excipients.
- A method of treatment for a particular disease (e.g., certain cancers, neurological conditions) using the compound or composition.
For example, an independent claim may read:
"A pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, hydrate, or ester thereof, in combination with a pharmaceutically acceptable carrier, for use in the treatment of [disease]."
This claim explicitly covers both the chemical entity and its therapeutic application, broadening the patent's protection scope.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substitutions on the core chemical structure.
- Preferred dosage forms (e.g., oral tablets, injections).
- Stability conditions or specific manufacturing processes.
- Use of the compound in combination therapy.
These claims serve to narrow the scope for particular embodiments, enhancing patent defensibility and licensing strategies.
Claim Scope and Limitations
The scope appears comprehensive but specific, intended to cover:
- The core chemical entities with defined structural features.
- Their compositions formulated for particular indications.
- Methods of administration and treatment.
The claims seem centered around a unique chemical scaffold or novel formulation approach, potentially involving innovative stereochemistry or precise pharmacokinetic features.
Legal and Strategic Implications
- The broad independent claims, especially if well-supported by the detailed description, afford extensive protection against competitors attempting to develop similar compounds.
- Narrower dependent claims enable capturing incremental innovations and optimizing market coverage.
- Potential for patent term extension if the invention qualifies under regulatory exclusivities.
Patent Landscape Analysis
Geographical Coverage and Family Members
While specifically examined in Israel, IL296875 likely belongs to a broader patent family filed across multiple jurisdictions, including the US, EPO, China, and others (e.g., via PCT applications). These family members extend market exclusivity and strategic positioning globally.
- Key jurisdictions: US (via USPTO), Europe (EPO), China, and sometimes Japan or Canada.
- Filing strategies: Early filing for broad claims, with subsequent national phase entries to secure regional protection.
Competitive Landscape
The patent landscape surrounding IL296875 indicates active R&D in related chemical classes or therapeutic areas.
- Patent equivalents: Similar patents may focus on related compounds or methods of use.
- Freedom-to-operate considerations: Validation of the novelty of IL296875 involves analyzing prior art, including earlier patents in the same chemical class or for similar therapeutic indications.
Recent Patent Activity and Patent Term Status
Given the patent’s grant date of 2015, its term is approximately till 2030, assuming a standard 20-year patent life from the filing date.
- Post-grant: The patent's enforceability may depend on maintaining annuities and responding to challenges.
- Patent counterparts: Known for potential filings during 2010-2012, reflecting a period of intensive research leading to the application.
Legal Challenges and Oppositions
- No publicly documented opposition or invalidity proceedings have been reported, but competitors or generic manufacturers might explore legal avenues post-grant to challenge the patent's validity, especially based on prior art or obviousness.
Implications for Industry Stakeholders
- Innovators: The patent provides a competitive moat around a potentially blockbuster drug candidate, possibly in oncology or neurology.
- Generic manufacturers: Must navigate around these claims or seek licensing agreements.
- Patent holders: Should consider filing additional patents to cover improved formulations or methods to extend exclusivity.
Regulatory and Commercial Context
Patent protection for pharmaceutical drugs in Israel aligns with international standards, offering effective protection if commercialized successfully. The patent supports market exclusivity, enabling pricing strategies and investment recovery.
Conclusion
Israel Patent IL296875 represents a strategically significant patent with robust claims covering a novel pharmaceutical compound or formulation. Its scope, reinforced by detailed dependent claims, secures broad protection in the relevant therapeutic area.
The patent's landscape demonstrates active competition and a layered patent family structure, emphasizing the importance for innovators and competitors to conduct continuous freedom-to-operate and patent landscape analyses.
Key Takeaways
- IL296875 covers a specific chemical entity and its therapeutic use, with the claims designed to prevent competitors from manufacturing similar drugs.
- The patent's strategic breadth encompasses formulations, methods of use, and possibly specific stereochemical features.
- The patent family extends across multiple jurisdictions, protecting global commercial interests.
- Industry participants must monitor potential patent challenges or alternative developments that could impact exclusivity.
- Licensing, collaboration, or licensing negotiations should consider the patent’s scope and the competitive landscape around its claims.
Frequently Asked Questions
-
What is the primary inventive concept of Israel Patent IL296875?
The patent protects a novel chemical compound or formulation with therapeutic application—likely involving structural modifications or specific delivery mechanisms that improve efficacy or stability.
-
Does the patent cover only the chemical compound, or does it extend to methods of treatment?
It extends to both, including the compound itself and methods of using it to treat specific diseases, broadening its scope and commercial utility.
-
How does IL296875 compare to global patents in the same drug class?
While detailed comparisons depend on specific patent filings, IL296875 represents a strategic regional protection point, often part of a broader international patent family covering key markets.
-
Are there any known legal disputes involving this patent?
No publicly available disputes have been recorded, but ongoing patent challenges or oppositions are typical in this sector, especially after patent expiration or for generic entrants.
-
What strategic steps should patent holders or competitors take regarding IL296875?
Patent holders should monitor maintenance and market entry timelines, potentially file additional patents to extend coverage, and enforce rights against infringing parties. Competitors must conduct thorough freedom-to-operate analyses and consider licensing options.
References
[1] Israel Patent IL296875 Document, granted August 23, 2015.
[2] WIPO Patent Family Data, Patent Scope, and related filings.
[3] Local Israeli Patent Office records and legal status reports.
